Dasatinib 化学構造
分子量: 488.01

高品質保証

文献中の引用(62)

カスタマーフィードバック(10)

MSDS

製品説明

  • Compare Src Inhibitors
    Src製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 Dasatinib は、野生型ablとSrcのためのSrc/abl阻害剤で、IC50 がそれぞれ 0.6 nM と 0.8 nMです。
ターゲット Abl Src c-Kit (WT)/c-Kit (D816V)
IC50

0.6 nM

0.8 nM [1]

79 nM/37 nM [2]
In vitro試験 Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
M07ep210 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLjO|IhcA>? NHHaRmlFVVOR M2PXUmlEPTB;MD6wNFAxPyEQvF2= MWexO|k2PjB6MB?=
K562 MnnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorVO|IhcA>? MlHnSG1UVw>? MVXJR|UxRTBwMECxJO69VQ>? NV7TPGlKOTd7NU[wPFA>
M07e NXWzeHd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\4XIwzPzJiaB?= NVrsb2YyTE2VTx?= NF;1XI5KSzVyPUCuNFAyOiEQvF2= M2PRUlE4QTV4MEiw
ALL3 M1SySmN6fG:2b4jpZ{BCe3OjeR?= NHXQUIcxNjIQvF2= NXOxZ21rPzJiaB?= M3vG[GROW09? NGHEN2RKSzVyPUCuNFAxPCEQvF2= MmnYNVk5QDl3NEC=
CML NXy3TIMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjsVmdoOjBibXnu NIHFTFlFVVOR NIDwRY9KSzVyPUCuNFAyKM7:TR?= M3\1S|E6OjF7MEG2
BA/F3 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV[3NkBp NIXZTJpFVVOR MVnJR|UxRTZwNUi5JO69VQ>? M17G[lI{ODh6NkS0
BA/F3 NVfD[VE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYe3NkBp Ml7zSG1UVw>? NIfnXYJKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW|c3nu[{BD[3JvQXLsJG0{PTGWIH31eIFvfCC5aYToJGlEPTBib3[gNE4xODB6M988US=> M1zLWlI{ODh6NkS0
BA/F3 Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rndFczKGh? NGfONGRFVVOR NHn6N|dKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW|c3nu[{B4cWymIIT5dIUhSmO{LVHicEB4cXSqIFnDOVAhd2ZiMD6wNFQ2|ryP MoP6NlMxQDh4NES=
BA/F3 M371NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljhO|IhcA>? MYLEUXNQ NYPFbY9TUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBVOzF3STDteZRidnRid3n0bEBKSzVyIH;mJFEvPzF2zszN MVeyN|A5QDZ2NB?=
BA/F3 NFnadZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;IO|IhcA>? Mon5SG1UVw>? NW\QbYd5UW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiRkS4OnMhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxODoQvF2= NUj4NHlyOjN|MEG3NFM>
BA/F3 NFLKV5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLOO|IhcA>? MU\EUXNQ MXvJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBGOjV3SzDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECzNu69VQ>? M4jJbFI{OzBzN{Cz
BA/F3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUO3NkBp MXzEUXNQ M1mzXGlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEd{NUDFJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFUy|ryP M{\vO|I{OzBzN{Cz
BA/F3 M4\IVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDIemk4OiCq Mm\vSG1UVw>? Ml\jTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhWTJ3MligcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwPO69VQ>? MViyN|MxOTdyMx?=
BA/F3 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU[3NkBp MXHEUXNQ NVzncHB3UW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiRUO1PXYhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOTQQvF2= M1:4ZlI{OzBzN{Cz
BA/F3 NGrIUZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LvR|czKGh? NVjH[HBETE2VTx?= NVHwdWhHUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIIfpcIQhfHmyZTDCR3IuSUKOIHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNVnPxE1? Ml3JNlM{ODF5MEO=
BA/F3 NHLJbY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV23NkBp M3v6XmROW09? Mmm3TY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhYTJ3M1igcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNlPPxE1? NEnH[m0zOzNyMUewNy=>
BA/F3 NHPISmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1K2ZVczKGh? M3n2VWROW09? M1LrXGlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFR|MUXJJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMz62{txO M{fmbVI{OzBzN{Cz
BA/F3 Mn7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjDUWY4OiCq MYPEUXNQ Mm\xTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghUW6qaXLpeIlwdiC5aYToJGlEPTBib3[gNk42|ryP NH\HeogzOzNyMUewNy=>
T cell NIPDWXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXG3NkBp NF6wWFhFVVOR MlTBTY5pcWKrdIOgZY51cSCFREOtJIFv\CCjboTpJGNFOjhvaX7keYNm\CCWIHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5yMEROwG0> MkHlNVcyPTR3MUK=
WiDr MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVe3NkBp MYnEUXNQ NWKyUlVNUUN3ME2wMlA2OiEQvF2= Mne2NVU3OTV3MUK=
PC3 NHH4[WdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\UO|IhcA>? MmjWSG1UVw>? M1nQTmlEPTB;MD6wNFk1KM7:TR?= NYjKXWsyOTV4MUW1NVI>
MDA-MB-231 MnHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjVcVQ4OiCq MmLESG1UVw>? NIHjZ5JKSzVyPUCuNFEzKM7:TR?= NWLLR4ZyOTV4MUW1NVI>
Hs578T NUn4dmJ4S3m2b4TvfIlkKEG|c3H5 M4rt[|czKGh? MWrEUXNQ NU\iNIM4T0l3ME2wMlA{KM7:TR?= M{XWc|I1ODF3M{K3
HMEC MU\DfZRwfG:6aXOgRZN{[Xl? MVq3NkBp MoK4SG1UVw>? M{jRU2dKPTB;MT64JO69VQ>? NGfBUYczPDBzNUOyOy=>
DU145 NGTnRVVEgXSxdH;4bYMhSXO|YYm= MVe3NkBp M3y0VmROW09? M{fCWGdKPTB;MD6xOkDPxE1? NXrBNGhrOjRyMUWzNlc>
U251 NGjXTXhEgXSxdH;4bYMhSXO|YYm= NYX3NYh3PzJiaB?= MXvEUXNQ M1XFPGdKPTB;Mj64NUDPxE1? NELKSXgzPDBzNUOyOy=>
NCI60 MmPZR5l1d3SxeHnjJGF{e2G7 NHnQNFA4OiCq MoCzSG1UVw>? M3uyOmdKPTB;NT63JO69VQ>? M3rlXFI1ODF3M{K3
MALME-3M MVTDfZRwfG:6aXOgRZN{[Xl? NEXXOYY4OiCq NH7VN2pFVVOR M4PCemdKPTB;Nj62NUDPxE1? NEW1cngzPDBzNUOyOy=>
KM12 M3;GeGN6fG:2b4jpZ{BCe3OjeR?= NILRSlY4OiCq NF7jZ4dFVVOR MmLGS2k2OD15LkS0JO69VQ>? Mm\KNlQxOTV|Mke=
SW620 Mlq5R5l1d3SxeHnjJGF{e2G7 Ml\LO|IhcA>? MXjEUXNQ NEPUbVZIUTVyPUiuOFMh|ryP NHPHbmkzPDBzNUOyOy=>
RXF 393NL Mom1R5l1d3SxeHnjJGF{e2G7 MmjKOEBl[Xm| M{\mcGROW09? NELjbmJKSzVyPUCuNFIyPyEQvF2= NUP3d5dnOjN{NUOwO|Q>
LXFA 983L M1mxN2N6fG:2b4jpZ{BCe3OjeR?= M{juSFQh\GG7cx?= MUHEUXNQ NFLMNJNKSzVyPUCuNFU3PSEQvF2= NHT0PXAzOzJ3M{C3OC=>
PRXF DU145 NF;HT41EgXSxdH;4bYMhSXO|YYm= MXK0JIRigXN? M37SVWROW09? NGS3e|VKSzVyPUCuNFYzOyEQvF2= NFvvRnYzOzJ3M{C3OC=>
PAXF 1657L MlKxR5l1d3SxeHnjJGF{e2G7 NH73WYg1KGSjeYO= NVvDOG1WTE2VTx?= MmnFTWM2OD1yLkGyNUDPxE1? NVfE[2s5OjN{NUOwO|Q>
CXF 1103L NWrsSGlUS3m2b4TvfIlkKEG|c3H5 M{TZWlQh\GG7cx?= NFnXOWtFVVOR NITqPFNKSzVyPUSuN|Yh|ryP M1[1NFI{OjV|MEe0
GXF251L MWrDfZRwfG:6aXOgRZN{[Xl? MkLHOEBl[Xm| NVz3[IxjTE2VTx?= M{HtdmlEPTB;Mj6yOUDPxE1? M33GclI{OjV|MEe0
NCI-H23 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13qc|czKGh? MonjSG1UVw>? MXHJR|UxRTJwMkeg{txO MYKyN|UzOTB{MB?=
HCT116 NXfuUHcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17i[VczKGh? NYXrO2U{TE2VTx?= MljxTWM2OD1{LkOg{txO M3L3WlI{PTJzMEKw
MCF7 Mlr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoizO|IhcA>? MnnESG1UVw>? MmPOTWM2OD1{LkW3JO69VQ>? MmfZNlM2OjFyMkC=
NCI-H460 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDh[HA4PzJiaB?= NVz4[2VSTE2VTx?= Mkn6TWM2OD16Lkm5JO69VQ>? Mof5NlM2OjFyMkC=
DLD1 NHTX[4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUH2boJ4PzJiaB?= MUPEUXNQ MXXJR|UxRTRwNjFOwG0> NWDrToNUOjN3Nke5OlA>
NCI-H661 NYm4enFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nGU|czKGh? MkfRSG1UVw>? NHHWSYlKSzVyPUeuPEDPxE1? MnzMNlM2Pjd7NkC=
A549 M3jLSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{mzblczKGh? MnXuSG1UVw>? MkjRTWM2OD16LkKg{txO M2P6PFI{PTZ5OU[w
U937 M4j0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFKxdo84OiCq M333WmROW09? NEjBe3VKSzVyPUGyMlIh|ryP NYj2UWlDOjN3Nke5OlA>
HEK293 NVLjZWs{TnWwY4Tpc44hSXO|YYm= NIjPVZkyOMLizszN M3:zOWROW09? MWrJcoR2[2W|IHLpcoRqdmdiYX\mbY5qfHlidH:gbJVu[W5iZoXscE1t\W6pdHigTIl{NXSjZ3fl[EBOgXRzIHvpcoF{\SCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{KHerdHigTWM2OCCxZjCwMlA3O87:TR?= NH\TfWQzOjd5ME[xNC=>
HUVEC M2jMRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2D2WFAvOTYEoN88US=> NWLuTGh5PzJiaB?= NVP6fIh{TE2VTx?= M4DEV2lv\HWlZYOgZY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiY3:tZ5VtfHW{ZXSge4l1cCC4YYPjeYxieiC|bX;veIghdXW|Y3zlJINmdGy|IHHzd4V{e2WmIHHzJGlvcGmkaYTpc44hd2ZiY3XscEBoem:5dHigZZQhOC5zNTD1US=> MnrjNlI5PTN7OUO=
HUVEC NFztXXlHfW6ldHnvckBCe3OjeR?= NGTEfmkyPcLizszN M364[VczKGh? M2\YO2ROW09? MkT0TY5lfWOnczDhcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCrbjDIWXZGSyClbz3jeYx1fXKnZDD3bZRpKH[jc3P1cIFzKHOvb3;0bEBufXOlbHWgZ4VtdHNiYYPz[ZN{\WRiYYOgTY5pcWKrdHnvckBw\iCwZYT3c5JsKG[xcn3heIlwdiCjdDCxMlghfG9iMUWgeW0> NV;MR21wOjJ6NUO5PVM>
Plasmodium falciparum MmXSSpVv[3Srb36gRZN{[Xl? NH;3XVgyOMLizszN NITkU4oyPSCvaX6= MmKwSG1UVw>? M17qVWlvcGmkaYTzJHBt[XOvb3TpeY0h\mGuY3nwZZJ2dSCycn;sbYZmemG2aX;uJIJ6KGmwaHnibZRqdmdidHjlJGZ2dmO2aX;uJI9nKFCoQ1TQT|EheHKxdHXpckB4cXSqIFnDOVAhd2ZiMT6xO:69VQ>? MmPsNlQ2PTB|M{C=
PC3 NXHkVGFOTnWwY4Tpc44hSXO|YYm= M3;IcFAvOSEQvF2= MYO1JIg> M{PJTWROW09? NYriPHZUUW6qaXLpeJMhcHWvYX6gVGM{KGOnbHygZYRp\XOrb36gZZQhOTByIH7N MVuxPVQ3Ojl5NR?=
DU145 M3rremZ2dmO2aX;uJGF{e2G7 NI[y[JgxNjFizszN M1nmT|UhcA>? MU\EUXNQ Ml;pTY5pcWKrdIOgbJVu[W5iRGWxOFUh[2WubDDh[Ihme2mxbjDheEAyODBibl2= NFLHPIgyQTR4Mkm3OS=>
PC3 MlG5T4lv[XOnIFHzd4F6 NIWxNZcxNjFizszN NVvzcGpGPSCq MXzEUXNQ M2HrV2lvcGmkaYTzJINUemNiaX6gbJVu[W5iUFOzJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBUemNiWUSxOkBt\X[nbDDheEAyODBibl2= Mo\tNVk1PjJ7N{W=
DU145 M3r5c2tqdmG|ZTDBd5NigQ>? MkflNE4yKM7:TR?= MknYOUBp MnvpSG1UVw>? NGi3boRKdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCVcnOgXVQyPiCuZY\lcEBifCBzMECgcm0> MXqxPVQ3Ojl5NR?=
PC3 MYjLbY5ie2ViQYPzZZk> NGXqUVIxNjFizszN NIfFbIg2KGh? MmT2SG1UVw>? MlXDTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCSQ{OgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI9zgWyjdHXkJGZCUyC\NUe2M3k2PzdibHX2[Ywh[XRiMUCwJI5O Mon4NVk1PjJ7N{W=
DU145 NHr1TpdMcW6jc3WgRZN{[Xl? MmexNE4yKM7:TR?= M2\6cVUhcA>? NVzKTIdkTE2VTx?= MmDMTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCGVUG0OUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhTkGNIGm1O|YwYTV5NzDs[ZZmdCCjdDCxNFAhdk1? MYexPVQ3Ojl5NR?=
Huh7 NF;VXXRCdnSrdnnyZYwhSXO|YYm= NYnVeIRjOi53IN88US=> NY\hXHlGPCCmYYnz M1vvfWROW09? MXnJcohq[mm2czD2bZJidCC|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIh2dWGwIFj1bFch[2WubIOgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJZqemGuIHXueoVtd3CnIIDyc5RmcW5id3n0bIlvKHCncnnueYNt\WG{IILl[4lwdiCjdDCyMlUhfU1? MkLTNVc{PjB4N{[=
C6/36 MoDFRY51cX[rcnHsJGF{e2G7 M33ke|IvPSEQvF2= NYW2dXpQPCCmYYnz M3XiemROW09? NYDtN2l5UW6qaXLpeJMhfmm{YXygd5Bz\WGmIHnuJGRmdme3ZTD2bZJ2ey2rbn\lZ5Rm\CCjc3nhckB1cWencjDtc5NyfWm2bzDDOk8{PiClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yhfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjD3bZRpcW5icHXybY52[2ynYYKgdoVocW:wIHH0JFIvPSC3TR?= NF3EWJMyPzN4ME[3Oi=>
U937 M3nRRWZ2dmO2aX;uJGF{e2G7 MY[xJO69VQ>? NIHpepIyKGh? M{e5e2ROW09? MkfrVoVlfWOnczDiZZNidCCWTl\hcJBp[SC{ZXzlZZNmKGmwIHj1cYFvKFV7M{egZ4VtdHN? MlHtNVc3QDRyOUm=
U937 MU\GeY5kfGmxbjDBd5NigQ>? MUKxJO69VQ>? NWCwOoVXOSCq NVfRVpZjTE2VTx?= NI[zNVVT\WS3Y3XzJGxRWy2rbnT1Z4VlKFSQRnHsdIhiKHKnbHXhd4UhcW5iaIXtZY4hXTl|NzDj[Yxtew>? Mmq2NVc3QDRyOUm=
murine mast cell MV\GeY5kfGmxbjDBd5NigQ>? MojuNUDPxE1? M4LtNlI1KGh? NV;MRodmTE2VTx?= NVzVUIc5UW6qaXLpeJMh[W62aXflck1qdmS3Y3XkJGlNPiC|ZXPy[ZRqd25iaX6gTYdGKHC{aX3l[EBud3W|ZTDtZZN1KGOnbHzzJIF1KDFidV2= MVKxO|Y5PDB7OR?=
BV-173 NUewXHFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTBwMECwNFAxOTB7IN88US=> M1TOeHNCVkeHUh?=
K-562 MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzsfHFKSzVyPUCuNFAxODByMk[2JO69VQ>? MX3TRW5ITVJ?
BL-70 Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HsT2lEPTB;MD6wNFAxODB6MkKg{txO MX3TRW5ITVJ?
EM-2 M3;qXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXnPJA2UUN3ME2wMlAxODByMUC4JO69VQ>? M17QNHNCVkeHUh?=
LAMA-84 M{LOR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2m2U2lEPTB;MD6wNFAxODN{MTFOwG0> MW\TRW5ITVJ?
MEG-01 MoG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3rTWM2OD1yLkCwNFAxQThizszN NGrrcZVUSU6JRWK=
EoL-1-cell NEjIcm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HDNWlEPTB;MD6wNFAxOTNzIN88US=> M4rOSXNCVkeHUh?=
CTV-1 M3zTRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDDUmhKSzVyPUCuNFAxODRyNDFOwG0> NITkW3JUSU6JRWK=
TE-15 NXfOOYM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn21TWM2OD1yLkCwOVg6KM7:TR?= NHLweFhUSU6JRWK=
NOS-1 NUPNWJlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTuS3hKSzVyPUCuNFA3OTNizszN MnHQV2FPT0WU
D-336MG MkP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHSTWM2OD1yLkCwOlMh|ryP M{HVc3NCVkeHUh?=
LB1047-RCC M3uzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXYSIRtUUN3ME2wMlAxQTh7IN88US=> M3fKXHNCVkeHUh?=
LB996-RCC MnjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTBwMEC5PVEh|ryP MV7TRW5ITVJ?
SW982 M1i5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPL[VNKSzVyPUCuNFEyOTVizszN NW[2NXB[W0GQR1XS
TK10 MkD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jTWWlEPTB;MD6wNVE4PCEQvF2= NWqzUWtuW0GQR1XS
A704 NFvaN3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HGS2lEPTB;MD6wNVQ6OSEQvF2= NYSzcGVKW0GQR1XS
TE-8 NGn5WZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojMTWM2OD1yLkCxOVc3KM7:TR?= NU\uVm9jW0GQR1XS
DOHH-2 NH3NdlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLLW4pKSzVyPUCuNFE4OTlizszN MWPTRW5ITVJ?
HOP-62 NX3GVIVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\PTWM2OD1yLkCxPFM1KM7:TR?= NVfzc3hsW0GQR1XS
TE-12 NFzPbFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjJTWM2OD1yLkCxPFYyKM7:TR?= NWr6[YZWW0GQR1XS
KGN M3;XfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnIbYlzUUN3ME2wMlAyQTR{IN88US=> NV62fFh4W0GQR1XS
NCI-H1648 NH3rfJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrwdY97UUN3ME2wMlAzODFzIN88US=> M3npOXNCVkeHUh?=
OS-RC-2 Mkn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwMEKwN{DPxE1? NGrhUIJUSU6JRWK=
GB-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;IOHNxUUN3ME2wMlAzOTV5IN88US=> NEfBcYFUSU6JRWK=
RXF393 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jyO2lEPTB;MD6wNlM2PyEQvF2= Ml7IV2FPT0WU
LC-2-ad M1XTVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXe3[I9yUUN3ME2wMlAzPTh4IN88US=> NGj2d25USU6JRWK=
KS-1 M162Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1KwRmlEPTB;MD6wNlc{KM7:TR?= NYrnOlk3W0GQR1XS
ETK-1 MmrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwMEK4N|Ih|ryP NEjENVRUSU6JRWK=
SW954 M1y1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjGSXc{UUN3ME2wMlAzQTJ5IN88US=> NIn0Z5pUSU6JRWK=
Becker MoXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwMEOwNFMh|ryP NGP3OXlUSU6JRWK=
MZ1-PC M4rIVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPETWM2OD1yLkCzNVE6KM7:TR?= NWfsVGZnW0GQR1XS
ES6 NYm3ZXh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWi3XXM2UUN3ME2wMlA{OTl|IN88US=> NUfNbmxtW0GQR1XS
KURAMOCHI NYe5OJJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HKfGlEPTB;MD6wN|Q5PyEQvF2= MVXTRW5ITVJ?
CGTH-W-1 MlvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLKTWM2OD1yLkCzOVQ5KM7:TR?= NVjF[XQyW0GQR1XS
VA-ES-BJ Mn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHTVWxKSzVyPUCuNFM6ODJizszN MofDV2FPT0WU
LXF-289 NInBUG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPwbGxKSzVyPUCuNFM6PTZizszN Ml21V2FPT0WU
MPP-89 NFXIXFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULhdGhrUUN3ME2wMlA1ODR7IN88US=> NX\uSmdNW0GQR1XS
SW872 M4HnWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3QTWM2OD1yLkC0NVYyKM7:TR?= MlT2V2FPT0WU
SNB75 M1OzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nmZ2lEPTB;MD6wOFQ{PSEQvF2= NX6xUI1tW0GQR1XS
PSN1 M{PlR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvNc3pbUUN3ME2wMlA1PDd2IN88US=> MkDWV2FPT0WU
LB831-BLC MmHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\zTWM2OD1yLkC0OlA6KM7:TR?= MV\TRW5ITVJ?
MFH-ino NWDTeFliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPJZ2NKSzVyPUCuNFQ4OjRizszN M2fwT3NCVkeHUh?=
TGBC24TKB M4\aSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTyTWM2OD1yLkC0O|YyKM7:TR?= NHi2UG1USU6JRWK=
A388 NE\INnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;1[JpKSzVyPUCuNFUxQTVizszN NX\MVFU6W0GQR1XS
BB30-HNC MoDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\KTWM2OD1yLkC1OFM4KM7:TR?= MVvTRW5ITVJ?
GI-ME-N MlL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jqWGlEPTB;MD6wOlEyQCEQvF2= M1fsOXNCVkeHUh?=
TGBC1TKB MlziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[1OGUxUUN3ME2wMlA3OTZ2IN88US=> MUfTRW5ITVJ?
TE-10 MlTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3kN3dKSzVyPUCuNFY{PTdizszN NYLVNm5kW0GQR1XS
A498 NH3zRZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHf2eHJKSzVyPUCuNFczQDRizszN NIjYbWdUSU6JRWK=
TE-11 NWG5eHdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrPTZNPUUN3ME2wMlA4QDV6IN88US=> MoLaV2FPT0WU
BB65-RCC M{PhSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvwTI1lUUN3ME2wMlA5OjJ5IN88US=> NXXMV3RwW0GQR1XS
C2BBe1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnOdlVKSzVyPUCuNFg{ODhizszN NHzOfHZUSU6JRWK=
NCI-H747 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjKdZJnUUN3ME2wMlA5OzZ{IN88US=> MWTTRW5ITVJ?
IST-MES1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTBwMEi1OVIh|ryP MV\TRW5ITVJ?
KALS-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEm0RmFKSzVyPUCuNFk1QSEQvF2= MYfTRW5ITVJ?
GCIY MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\EXGlEPTB;MD6wPVY2PiEQvF2= MmrJV2FPT0WU
RL95-2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLqSVRUUUN3ME2wMlExOzhizszN NID1O21USU6JRWK=
TE-1 NGHrOVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4C3fGlEPTB;MD6xNFU1KM7:TR?= MX3TRW5ITVJ?
NCI-H1355 NXHSWZBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\zd2lEPTB;MD6xNVAzQCEQvF2= NWrDbmZEW0GQR1XS
SW962 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrRRoVKSzVyPUCuNVEzQTJizszN NVTC[215W0GQR1XS
KLE NF7NUG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfGTWM2OD1yLkGxN|E4KM7:TR?= NFPHfphUSU6JRWK=
MC116 M1PlN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rze2lEPTB;MD6xNVQyKM7:TR?= M3\QPXNCVkeHUh?=
NMC-G1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwMUG2NFYh|ryP MWrTRW5ITVJ?
KU812 M163SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjGepRRUUN3ME2wMlEyQDh|IN88US=> M2q1R3NCVkeHUh?=
COLO-829 MkDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moj3TWM2OD1yLkGyNlE{KM7:TR?= MlrPV2FPT0WU
NTERA-S-cl-D1 NVPFNXdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYe3NoR6UUN3ME2wMlEzOjh|IN88US=> MWnTRW5ITVJ?
IST-MEL1 NFXCdnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\LTWM2OD1yLkGzOFUh|ryP NFnq[lJUSU6JRWK=
MLMA MljCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvseGU4UUN3ME2wMlE1ODN{IN88US=> MnHpV2FPT0WU
LS-123 MonCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfwcnVKSzVyPUCuNVQxPjRizszN NH7FfFJUSU6JRWK=
LB2518-MEL M2nYemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwMUSxOlIh|ryP NXjiWmVuW0GQR1XS
NB69 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfNTWM2OD1yLkG0OFM3KM7:TR?= NWT2foZWW0GQR1XS
8-MG-BA M4jxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2raZWlEPTB;MD6xOVQ2QCEQvF2= NFP2ZmdUSU6JRWK=
K5 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLtU5d2UUN3ME2wMlE3PDh7IN88US=> M4HNSnNCVkeHUh?=
KINGS-1 NEeySYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVO0NY9yUUN3ME2wMlE3PjZ4IN88US=> M{f5NHNCVkeHUh?=
SF268 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfk[I5GUUN3ME2wMlE4PDB2IN88US=> M{\QXXNCVkeHUh?=
PF-382 NFfIbWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHlfnZKSzVyPUCuNVc3PzhizszN M1rne3NCVkeHUh?=
SH-4 NHTJV3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHX6PXZKSzVyPUCuNVg1OTNizszN MlK0V2FPT0WU
NALM-6 M4XuWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3na[2lEPTB;MD6xPVI6PSEQvF2= MkHoV2FPT0WU
CP66-MEL NHPSbWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwMUm1N|Eh|ryP MXfTRW5ITVJ?
697 M4e4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnO5TWM2OD1yLkG5PVg4KM7:TR?= NWfvOFZtW0GQR1XS
CP67-MEL MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvrV2t1UUN3ME2wMlIxPDh6IN88US=> M{fCOXNCVkeHUh?=
DSH1 MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LKe2lEPTB;MD6yOFAxOSEQvF2= NFT4XFlUSU6JRWK=
HCE-4 NHf4OItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHjZnVKSzVyPUCuNlY1OzlizszN Mnq5V2FPT0WU
MZ2-MEL M{PPbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LRVWlEPTB;MD6yPFU{PyEQvF2= M1;IfHNCVkeHUh?=
BL-41 M1m0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwMkmxNlMh|ryP NHzFZ4RUSU6JRWK=
HUTU-80 M4ryb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfLTWM2OD1yLkOxOFIh|ryP MnPPV2FPT0WU
LOXIMVI M17FXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfoco55UUN3ME2wMlMyPTB|IN88US=> MWXTRW5ITVJ?
no-10 NXHmXXJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7Kc|RmUUN3ME2wMlMyQTNzIN88US=> Ml7oV2FPT0WU
KARPAS-422 MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULQelFwUUN3ME2wMlM{QTl5IN88US=> NU[0R4J2W0GQR1XS
SW684 MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlS3TWM2OD1yLkO0PVgh|ryP NF\BVHpUSU6JRWK=
SF126 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TQcmlEPTB;MD6zOVQyKM7:TR?= MX7TRW5ITVJ?
D-263MG MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIq1PYJKSzVyPUCuN|YzOjRizszN M1\VdnNCVkeHUh?=
OVCAR-4 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDOTWM2OD1yLkO3OFM{KM7:TR?= NY\V[3l[W0GQR1XS
BB49-HNC MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIH6WGlKSzVyPUCuN|g2QTlizszN M{LqUHNCVkeHUh?=
ONS-76 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfkTWM2OD1yLkSyPVUyKM7:TR?= MWHTRW5ITVJ?
MZ7-mel MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTBwNEe5NVEh|ryP Ml7VV2FPT0WU
RCC10RGB NXHG[oRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1S2bWlEPTB;MD60PVEyKM7:TR?= NGXVWXNUSU6JRWK=
BOKU MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvoXGttUUN3ME2wMlQ6OTN|IN88US=> M17pSXNCVkeHUh?=
no-11 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{K1NWlEPTB;MD61NFIzQCEQvF2= M{nJW3NCVkeHUh?=
IST-SL2 M3K1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwNUCzNFIh|ryP NVmyTXZlW0GQR1XS
RKO Mk\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwNUK5OlYh|ryP NInTSYVUSU6JRWK=
HT-144 MlvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjMc3VKSzVyPUCuOVM3ODlizszN NWmwdmEyW0GQR1XS
NCI-H446 M2nVT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLzTWM2OD1yLk[yO|Yh|ryP Mn[zV2FPT0WU
QIMR-WIL MontS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHXTHhKSzVyPUCuO|A3OjlizszN NXvxSIo2W0GQR1XS
MHH-PREB-1 NUTCR2VGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\lTWM2OD1yLke0OFY6KM7:TR?= MnrVV2FPT0WU
EW-16 M3S1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\hbVNKSzVyPUCuO|YyPzhizszN MVvTRW5ITVJ?
EW-24 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwN{ixOlUh|ryP NILKbFBUSU6JRWK=
LB373-MEL-D NF7xbmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDZTWM2OD1yLkiyOVA5KM7:TR?= NEXxPWRUSU6JRWK=
TE-9 NGS5TplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\aWGlEPTB;MD64O|U{OiEQvF2= NGTrSWRUSU6JRWK=
A3-KAW NV3vem5GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIP3bZBKSzVyPUCuPVg1PTJizszN MYTTRW5ITVJ?
A101D NXrWSnlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfrPZY{UUN3ME2xMlA{ODR|IN88US=> NIfZfJdUSU6JRWK=
OCUB-M Mm\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX25PGx[UUN3ME2xMlA1PDF{IN88US=> MlnqV2FPT0WU
ES4 NXnGTGl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTFwMEWxOFUh|ryP NFG2bFJUSU6JRWK=
TE-6 NHLXc2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTFwMkGyNlYh|ryP M2fPOXNCVkeHUh?=
D-502MG NYTMRZJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfEbJFVUUN3ME2xMlI{Ozd4IN88US=> M1HvXHNCVkeHUh?=
KNS-42 M4PlZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTFwMkS0NVIh|ryP NFzqfmVUSU6JRWK=
SNU-C2B Ml;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTFwM{C1PFkh|ryP MlrqV2FPT0WU
NCI-H1838 MkWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33MOGlEPTB;MT6zNFc{OyEQvF2= M3jrZnNCVkeHUh?=
NKM-1 NH7SN4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nDNGlEPTB;MT6zNFg2QSEQvF2= NFfSVJdUSU6JRWK=
GI-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoOyTWM2OD1zLkO2NlIh|ryP M{LSRXNCVkeHUh?=
NB5 M4noe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPqXZFKSzVyPUGuN|k5OjdizszN NF3tZmNUSU6JRWK=
CAS-1 MlHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jud2lEPTB;MT60NFk6OiEQvF2= MXvTRW5ITVJ?
HCE-T M2r5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTFwNU[3NVQh|ryP NIWycJhUSU6JRWK=
SBC-1 NVfRSHZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;lWWlEPTB;MT61O|k5PCEQvF2= MlH2V2FPT0WU
JiyoyeP-2003 NETsb5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDLOHhKSzVyPUGuO|M1PjZizszN MoPqV2FPT0WU
TE-5 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHpWVVKSzVyPUGuO|kyOzlizszN M4Sw[nNCVkeHUh?=
CAN MljFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\0TWM2OD1zLkiyNlUzKM7:TR?= M3jNZnNCVkeHUh?=
SK-UT-1 NIPu[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLzTWM2OD1{LkG2Olk{KM7:TR?= Mlr3V2FPT0WU
JVM-2 MnfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zaWmlEPTB;Mj6zOlI5PCEQvF2= MkLHV2FPT0WU
LB771-HNC NUXXWoM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3OSWlKSzVyPUKuOVc2PTFizszN M1PCOXNCVkeHUh?=
NCCIT M2jXS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTJwOE[2NVYh|ryP NYLsOHdiW0GQR1XS
NCI-H2126 MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoG1TWM2OD1{Lki3OVUzKM7:TR?= MnrmV2FPT0WU
Calu-6 M4Xkd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTNwMEW3OFEh|ryP NWDhbWN[W0GQR1XS
SK-LMS-1 NXuy[IRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1:0fmlEPTB;Mz6xNVg5PiEQvF2= M2fuTnNCVkeHUh?=
ARH-77 MnzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXlWY1KSzVyPUOuOFY6OTVizszN MYrTRW5ITVJ?
NB17 MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7rXGFKSzVyPUOuOlM5PDdizszN MoXOV2FPT0WU
A253 NIPpWo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\zZpY2UUN3ME2zMlc{OjR4IN88US=> M{DuSHNCVkeHUh?=
OPM-2 M3G5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTRwMke2PFUh|ryP NYKzSGJbW0GQR1XS
MV-4-11 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[5e|NLUUN3ME20MlM3PDV2IN88US=> MYLTRW5ITVJ?
SR MnTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjRdVNKSzVyPUSuOFk6PTRizszN Ml\CV2FPT0WU
KG-1 NIfHO5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHWU4xrUUN3ME20MlYxQDR3IN88US=> M4[4S3NCVkeHUh?=
OCI-AML2 NYC0cItXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPQcFZKSzVyPUWuPFYyPTRizszN M1[xXHNCVkeHUh?=
D-247MG MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULhOGVvUUN3ME22MlEzPTF7IN88US=> NGn5PXZUSU6JRWK=
DJM-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTZwNEi1OVgh|ryP NIrYcIpUSU6JRWK=
RPMI-6666 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nHbmlEPTB;Nz6yO|A3PyEQvF2= Ml\6V2FPT0WU
KARPAS-45 Ml7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;yTWM2OD15LkWxOlcyKM7:TR?= NUO5coRkW0GQR1XS
LP-1 NV3Q[29UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fHWWlEPTB;Nz61OFc5OiEQvF2= MVfTRW5ITVJ?
RS4-11 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zKbmlEPTB;Nz62OVc5PyEQvF2= MlLIV2FPT0WU
DU-4475 MkfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HJWWlEPTB;OD6yNVY2OiEQvF2= NFjXVpNUSU6JRWK=
MONO-MAC-6 MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRThwMkewOlYh|ryP NEfzO5BUSU6JRWK=
NCI-SNU-16 MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDIVXF{UUN3ME24MlU3OTJ6IN88US=> NF3pbGNUSU6JRWK=
SJSA-1 NYrRTox4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37LWmlEPTB;OD63NlgxPSEQvF2= MWrTRW5ITVJ?
MMAC-SF NIjjcFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\udYpKSzVyPUiuO|k{ODdizszN M{j0ZXNCVkeHUh?=
SK-NEP-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[xTWM2OD16Lki5NVU2KM7:TR?= Mn\0V2FPT0WU
J-RT3-T3-5 M3GwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWG0WlJwUUN3ME24Mlk3PTJ7IN88US=> MVvTRW5ITVJ?
SKM-1 M2\sNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljvTWM2OD17LkCxO|M1KM7:TR?= M{XJS3NCVkeHUh?=
LB2241-RCC M2jvUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjpZnFKSzVyPUmuNFIxOTJizszN NFHCWW1USU6JRWK=
SIG-M5 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTlwMEK0PVMh|ryP NX3MNo1xW0GQR1XS
EVSA-T MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPZTWM2OD17LkK3O|k{KM7:TR?= M1rZZ3NCVkeHUh?=
GT3TKB M1LZbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTlwM{W1OFYh|ryP MUPTRW5ITVJ?
NB6 NIC3T2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[xNWlEPTB;OT65NlI2QSEQvF2= MYPTRW5ITVJ?
EHEB NU\R[ox4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV64SYxiUUN3ME2xNE4xPjV4IN88US=> M2\JZnNCVkeHUh?=
HEL M4DRS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnrSZFKSzVyPUGwMlQ4PzZizszN NXy0W4dCW0GQR1XS
ALL-PO MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXqwRlFPUUN3ME2xNE44QTN6IN88US=> NYHUcFZmW0GQR1XS
TGW M2DPTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTFzLkK4Nlgh|ryP M3H2Z3NCVkeHUh?=
BC-3 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTF{LkGxN|gh|ryP NGLPem9USU6JRWK=
IA-LM NFjZc5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVT5T21[UUN3ME2xNk41PDR3IN88US=> M3fQeHNCVkeHUh?=
UACC-257 NV;UVmFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHYWIJKSzVyPUGyMlkyQThizszN NF6xUVJUSU6JRWK=
KP-N-YS Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DoVGlEPTB;MUKuPVI5OyEQvF2= NH61TppUSU6JRWK=
Raji MlvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\ucpFKSzVyPUGzMlc1QTdizszN NXuzeYhCW0GQR1XS
SF539 NFHBWGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLmTWM2OD1zMz64OVU4KM7:TR?= NVK0SmZNW0GQR1XS
DMS-153 MnjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYm4VYZFUUN3ME2xOE4xODJ6IN88US=> M2nCOXNCVkeHUh?=
L-540 NHjV[4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTF3LkC2O|Ih|ryP MXHTRW5ITVJ?
MN-60 NIHrZoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTF3LkG5O|kh|ryP NEfiSIlUSU6JRWK=
RPMI-8866 NUnwd2M4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILkTXJKSzVyPUG3MlQ1PTRizszN M1nZbHNCVkeHUh?=
NCI-H510A MlGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnqPXJKSzVyPUG5MlM6PzNizszN NFnBZopUSU6JRWK=
NB13 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTF7LkS4O|ch|ryP NYXlflZqW0GQR1XS
HAL-01 NYrtcGJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LwVGlEPTB;MUmuO|U1OyEQvF2= MUjTRW5ITVJ?
NCI-H720 M1T4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTJyLkK3N|Mh|ryP NFHWZ2JUSU6JRWK=
REH M1zmfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofnTWM2OD1{MD62N|U4KM7:TR?= Mn\wV2FPT0WU
KNS-81-FD NXvNeXoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7xXJJKSzVyPUKzMlE1PiEQvF2= MorKV2FPT0WU
HC-1 M3j0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDmTWM2OD1{ND61OVUyKM7:TR?= MWHTRW5ITVJ?
NCI-H2141 NXjlSXJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzuNJpKSzVyPUK0Mlc4PTRizszN MUjTRW5ITVJ?
MOLT-4 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13xRmlEPTB;Mk[uOlc2OyEQvF2= M2[zeHNCVkeHUh?=
OMC-1 Mly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXy[pQxUUN3ME2yO{4yPDJ{IN88US=> NGjVOndUSU6JRWK=
LC-1F NWPmT2xtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlyxTWM2OD1{Nz6zNlQ2KM7:TR?= M2jtb3NCVkeHUh?=
NCI-H1304 NVr6So5XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nnUWlEPTB;MkiuNVYzQCEQvF2= NX7H[VlYW0GQR1XS
BC-1 NWLhU2VQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\0TWM2OD1{OD62OVEh|ryP NWOz[JRPW0GQR1XS
NCI-H64 MoHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LERWlEPTB;MkmuOlI2OyEQvF2= NIS4TFJUSU6JRWK=
MOLT-16 M4SxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jGdmlEPTB;MkmuOlI6OiEQvF2= MmfuV2FPT0WU
U-87-MG NGrsR5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljOTWM2OD1|MD63OlYh|ryP MWjTRW5ITVJ?
GAK NVriWIVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\aVJZ4UUN3ME2zNU4zPjh4IN88US=> MUfTRW5ITVJ?
ES8 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jacGlEPTB;M{KuNVI2OiEQvF2= MoXzV2FPT0WU
HCC1599 NUP6UVVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Hy[2lEPTB;M{KuN|MzPSEQvF2= NH;0NFhUSU6JRWK=
EB-3 M2nVOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk[xTWM2OD1|ND6zNVE4KM7:TR?= M4nKe3NCVkeHUh?=
HCC1187 M4nUWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDyTWM2OD1|NT64NFUzKM7:TR?= MUfTRW5ITVJ?
SK-PN-DW NY\wNYNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTM[pg5UUN3ME2zOk4yQTR|IN88US=> NInVU|FUSU6JRWK=
JVM-3 NWKzdplsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPLbXk4UUN3ME2zO{4zOzN6IN88US=> MVnTRW5ITVJ?
HCC2157 NVPORZE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnjeXdHUUN3ME2zO{46QTR4IN88US=> NV2zdWp7W0GQR1XS
A4-Fuk MnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTN6LkGwNFkh|ryP NH3DTWJUSU6JRWK=
COR-L279 NFjDS5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTRyLkK4OVEh|ryP MVHTRW5ITVJ?
DEL MmjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPESI1LUUN3ME20NU46ODh4IN88US=> NHL6TlNUSU6JRWK=
NCI-H1395 MorMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vHW2lEPTB;NEKuNFE3OyEQvF2= M{DiWXNCVkeHUh?=
MHH-NB-11 M3\kfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTR|LkC4NVgh|ryP NGTURlhUSU6JRWK=
NCI-H2107 NFm2U49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTR|LkS4OFYh|ryP NX7hWYoyW0GQR1XS
NEC8 NYLRRWZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnEXGc6UUN3ME20OE4{OzZizszN NF;0T3lUSU6JRWK=
COLO-684 NUTaVplPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TVRWlEPTB;NE[uNlI2QCEQvF2= NIn4bmtUSU6JRWK=
LS-411N NILyNlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\4[WE5UUN3ME20PE41PzR6IN88US=> M2mxeXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo試験 Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]
臨床試験 Dasatinib has entered in a phase II clinical trial in the treatment of hemangiopericytoma and gastrointestinal stromal tumor.
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Kinase autophosphorylation assays Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.

細胞アッセイ:

[1]

細胞株 Ba/F3 cell lines
濃度 ~32 nM
反応時間 72 hours
実験の流れ

Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.

動物実験:

[3]

動物モデル EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
製剤 DMSO
投薬量 30 mg/kg
投与方法 Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Dasatinib SDF
分子量 488.01
化学式

C22H26ClN7O2S

CAS No. 302962-49-8
保管 3年-20℃
2年-80℃in solvent
別名 BMS-354825
溶解度 (25°C) * In vitro DMSO 98 mg/mL (200.81 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 4% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide

文献中の引用 (62)

Frequently Asked Questions

  • Question 1
    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

    Answer: Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related Src 阻害剤

  • Dasatinib Monohydrate

    Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.

  • SU6656

    SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.

  • PX-478 2HCl

    PX-478 2HClは一種の経口活性をしている、選択性的なHIF-1α阻害剤です。臨床1期。

  • Defactinib (VS-6063, PF-04554878)

    Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.

  • Saracatinib (AZD0530)

    Saracatinib(AZD0530)は、c-SrcのためのSrc阻害剤で、IC50 が2.7 nMです。

    Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

  • Bosutinib (SKI-606)

    Bosutinib(SKI-606)はそれぞれ1.2nMと1nMのIC50値による新しい二重Sarcoma/アベルソン(Src/Abl)チロシン・キナーゼ阻害剤です。

  • KX2-391

    KX2-391は、Srcのサブストレート結合部位を目標とする非常に選択的な非ATP Srcキナーゼ阻害剤で、Srcの高水準を表すガン細胞線で、非常に強い反増殖的な活性を示します。

  • PP1

    PP1は、Lck/Fynのための強力で選択的なSrc阻害剤で、IC50 が 5 nM/ 6 nMです。

  • PP2

    PP2は、Src キナーゼ阻害剤で、GST-Src活動を強力に禁止します。

最近チェックしたアイテム

Tags: Dasatinibを買う | Dasatinib供給者 | Dasatinibを購入する | Dasatinib費用 | Dasatinib生産者 | オーダーDasatinib | Dasatinib代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ